Researchers Develop Highly Sensitive PCR-Based Liquid Biopsy Cancer Dx

August 14, 2017
Researchers Develop Highly Sensitive PCR-Based Liquid Biopsy Cancer Dx
Source: Getty Images

A team of investigators from Stanford University has just released data on their efforts to develop a new iquid biopsy test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood using a relatively simple PCR-based assay.  

The results from this study—published today in The Journal of Molecular Diagnostics in an article entitled “Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA”—show that this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer. The test, which the researchers dubbed single-color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.

"For monitoring patient tumors, only a handful of blood tests are available that are limited to only several types of cancers,” explained senior study investigator Hanlee Ji, M.D., associate professor in the department of medicine at Stanford University and senior associate director of the Stanford Genome Technology Center. “Nearly all cancer patients require monitoring by whole-body imaging, which can be costly, complex, and time-consuming.”

In the new study, the researchers described the use of the test to analyze samples from six patients. Of these patients, five were previously diagnosed with colorectal cancer and one with cholangiocarcinoma. The research team was able to identify tumor-derived circulating DNA from three out of six patients. In one patient, the assay showed the presence of three different mutations. The three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.

“Molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread,” Dr. Li noted. “Moreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done."

The single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays. The main advantage is that the new technique does not rely on preamplification, which can introduce errors and biases.

“This approach relied on a double-stranded DNA intercalator dye and paired allele-specific DNA primer sets to determine an absolute count of both the mutation and wild-type–bearing DNA molecules present in the sample,” the authors wrote. “The cell-free DNA assay uses an input of 1 ng of nonamplified DNA, approximately 300 genome equivalents, and has a molecular limit of detection of three mutation DNA genome-equivalent molecules per assay reaction. When using more genome equivalents as input, we demonstrated a sensitivity of 0.10% for detecting the BRAF V600E and KRAS G12D mutations. We developed several mutation assays specific to the cancer driver mutations of patients' tumors and detected these same mutations directly from the nonamplified, circulating cell-free DNA.”

The investigators are optimistic about their finding and look forward to testing their assay on larger sample populations of cancer patients. Due to the speed of the assay and its reduced costs, the research team is hopeful that their test could be employed in an array of physician’s offices and clinics for routine cancer monitoring.  

"This test is simple enough to set up and analyze without extensive training, and, therefore, it can be implemented by anyone, making it highly accessible to any laboratory,” concluded lead study author Christina Wood-Bouwens, a research professional at Stanford University School of Medicine. “It has been truly motivating to work with a technology that will help transform the way that we monitor and treat individuals with cancer. I am excited to share our findings with the cancer research community." 

×

Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.